Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 20 Triple Negative Breast Neoplasms 6 Ovarian Neoplasms 3 Uterine Cervical Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Locally Advanced (Inoperable) or Metastatic Breast Cancer 2 Endometrial Neoplasms 2 Disease Progression 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1 Glioma 1 Fallopian Tube Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

Fulvestrant 19 Letrozole 10 Anastrozole 8 Capecitabine 5 palbociclib 4 olaparib 4 Paclitaxel 4 Injections 4 Goserelin 4 Docetaxel 4 trastuzumab deruxtecan 3 pyrotinib 3 exemestane 3 Vinorelbine 3 Aromatase Inhibitors 3 toripalimab 2 sacituzumab govitecan 2 ribociclib 2 eribulin 2 elacestrant 2 dalpiciclib 2 abemaciclib 2 Trastuzumab 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Everolimus 2 Dasatinib 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 AZD9833 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × capivasertib × Breast × Clear all

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡